COL5A2 and neoplasm: High expression of COL5A2 (HR=1.67, CI=1.01–2.76, p=0.044; Supplementary Figure S5a), FN1 (HR=2.15, CI=1.33–3.47, p=0.002; Supplementary Figure S5b), and elevated ECM signature scores (HR=1.83, CI=1.13–2.96, p=0.013; Supplementary Figure S5c) were independent adverse prognostic factors only in patients with tumours harbouring TP53-mutations.